AI-Driven CDMO Solutions for Advanced Protein Expression and Antibody Drug Development
The demand for high-quality recombinant proteins and antibody-drug conjugates (ADCs) continues to grow, yet the development pipeline remains challenged by long timelines, high failure rates, and escalating costs. Creative BioMart's AI-driven CDMO platform addresses these bottlenecks head-on by seamlessly integrating artificial intelligence with experimental biology.
We are pleased to invite Dr. Xiaoyu Zhu, Senior Business Development Manager at Creative BioMart, to present an in-depth look at our AI-powered CDMO solutions for advanced protein expression and antibody drug development.
In this webinar, Dr. Zhu will introduce Creative BioMart's integrated AI platform, which enables accurate 3D structure prediction, affinity maturation, immunogenicity risk assessment, and de novo antibody design — significantly reducing development time and cost. The session will cover our GMP-compliant facilities, scalable mammalian and microbial expression systems, and comprehensive quality control processes. Attendees will learn how our AI-first, dry-wet closed-loop approach achieves high success rates in antibody engineering and membrane protein production, supporting next-generation biotherapeutics.
Key topics to be discussed during the session:
- AI-powered 3D structure prediction and affinity maturation for antibody optimization
- De novo antibody design and immunogenicity risk assessment using proprietary AI models
- Scalable mammalian and microbial expression systems for membrane proteins and recombinant antibodies
- GMP-compliant manufacturing and quality control: LC-MS, iCIEF, CE-SDS, qPCR
Join us to explore how Creative BioMart's AI-first CDMO platform can accelerate your biologic development programs — from early-stage protein engineering through to GMP-grade manufacturing.
Register Now
Speaker
Xiaoyu Zhu, Ph.D.
Senior Business Development Manager at Creative BioMart
Dr. Xiaoyu Zhu serves as the Senior Business Development Manager at Creative BioMart, bringing decades of extensive experience in the fields of protein and antibody expression. Over the course of her career, she has successfully led dozens of CDMO projects, guiding them from early-stage development through to commercial readiness. Dr. Zhu has developed particularly deep expertise in protein expression, protein purification, and stable cell line generation. Her profound technical knowledge and hands-on experience in these critical areas have enabled numerous clients to overcome complex challenges, streamline their biomanufacturing processes, and accelerate the development of novel biologics and therapeutics.